| 79.97 0 (0%) | 02-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 93.4 | 1-year : | 109.09 |
| Resists | First : | 79.97 | Second : | 93.4 |
| Pivot price | 79.83  |
|||
| Supports | First : | 79.54 | Second : | 79.29 |
| MAs | MA(5) : | 79.94 |
MA(20) : | 79.78 |
| MA(100) : | 58.25 |
MA(250) : | 51.08 |
|
| MACD | MACD : | 2.5  |
Signal : | 3.3 |
| %K %D | K(14,3) : | 96.8 |
D(3) : | 95 |
| RSI | RSI(14): 79.6 | |||
| 52-week | High : | 79.97 | Low : | 36.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NARI ] has closed below upper band by 19.4%. Bollinger Bands are 96.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 80.09 - 80.49 | 80.49 - 80.82 |
| Low: | 79.02 - 79.45 | 79.45 - 79.81 |
| Close: | 79.34 - 80.01 | 80.01 - 80.57 |
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Wed, 19 Feb 2025
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment - GlobeNewswire
Wed, 19 Feb 2025
Inari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025 - Yahoo Finance
Sat, 15 Feb 2025
Stryker Acquires Inari Medical: A $4.7 Billion Healthcare Merger (SYK, NARI) - tradingcalendar.com
Wed, 12 Feb 2025
Inari Medical stock soars to 52-week high of $79.95 - MSN
Wed, 05 Feb 2025
Reasons to Retain Inari Medical Stock in Your Portfolio for Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 95.5 (%) |
| Shares Short | 2,480 (K) |
| Shares Short P.Month | 3,840 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.44 |
| Profit Margin | -13.7 % |
| Operating Margin | -4.4 % |
| Return on Assets (ttm) | -3.3 % |
| Return on Equity (ttm) | -17.8 % |
| Qtrly Rev. Growth | 21.3 % |
| Gross Profit (p.s.) | 8.51 |
| Sales Per Share | 9.81 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 87 (M) |
| PE Ratio | -59.24 |
| PEG Ratio | 0 |
| Price to Book value | 10.74 |
| Price to Sales | 8.15 |
| Price to Cash Flow | 330.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|